Unlike other available blood and urine tests, the miR Sentinel Prostate Cancer Test characterizes the entire prostate, allowing for more accurate results. If cancer is present, the results classify a patient’s condition into categories describing the risk level of developing aggressive disease.
The prostate naturally releases molecules into urine, including several different kinds of genetic material that vary depending on the presence and severity of prostate cancer. We extract and measure these fragments, known as small non-coding RNAs, using gene expression technology and a proprietary algorithm. The miR Sentinel Prostate Cancer Test is a standalone test – it does not rely on PSA or biopsy material.
This group has a molecular signature that is not consistent with those signatures known to have positive biopsy.
This majority of this group has a molecular signature that is consistent with the Grade Group 1 designation, the subgroup with the smallest probability of aggressive prostate cancer.
This group has an intermediate molecular signature not consistent with the NMEPC group, the Low-risk group and the High-risk group.
This group has molecular signature predominantly consistent with the biopsy Grade Group 5 designation, the subgroup with the largest probability of aggressive prostate cancer.
miR’s unique sncRNA extraction and interrogation techniques coupled with an advanced proprietary algorithm will allow physicians to confidently detect and classify prostate cancers with just one urine sample, reducing unnecessary prostate cancer diagnostic procedures and treatments.
Book an appointment with your doctor or urologist and request a prescription for the miR Sentinel Prostate Cancer Test™.
Provide a simple urine sample
in your doctor’s office
The report will be securely delivered to the provider who ordered the test, either via secure fax or our online provider portal through CareEvolve.
The miR Sentinel™ Prostate Cancer Test is commercially available in most US states as well as Puerto Rico. The Test is not currently available in New York, California, Pennsylvania, Maryland, Rhode Island and Washington, D.C. We are working to bring miR Sentinel™ to all 50 U.S. states, all territories and global markets including Canada, Israel and Singapore.
miR Scientific Collection Kits can be ordered by a healthcare provider over the phone, by contacting miR Scientific’s customer service team at 1-855-55CALLMIR.
miR Scientific is currently exploring insurance coverage and Medicare reimbursement with several carriers in the US and Puerto Rico but is currently an out-of-network provider. Patients will have the option of paying with credit card or we can assist with submitting out-of-network claims to their carrier. We plan to offer a patient assistance program called miR Access™ to support access to the test for those in need.
miR's Sentinel™ Prostate Cancer Test is currently only available through a health care provider. Please speak with your physician about possible testing options.
We're here to help! Visit our support center for FAQs and options to connect with a miR Sentinel expert directly.SUPPORT CENTER